NCT03059420 Genetic Studies of Strabismus, Congenital Cranial Dysinnervation Disorders (CCDDs), and Their Associated Anomalies
| NCT ID | NCT03059420 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Boston Children's Hospital |
| Condition | Congenital Fibrosis of Extraocular Muscles |
| Study Type | OBSERVATIONAL |
| Enrollment | 20,000 participants |
| Start Date | 2004-02-01 |
| Primary Completion | 2030-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 20,000 participants in total. It began in 2004-02-01 with a primary completion date of 2030-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to identify genes associated with impaired development and function of the cranial nerves and brainstem, which may result in misalignment of the eyes (strabismus) and related conditions.
Eligibility Criteria
Inclusion Criteria: * The Engle Lab is very interested in enrolling individuals with congenital conditions related to eye movement, cranial nerve and brainstem-based dysfunction, often broadly referred to as congenital cranial dysinnervation disorders (CCDDs). Exclusion Criteria: * Individuals with cranial nerve disorders associated with known disorders, such as Saethre-Chotzen associated with established genetic mutations, or acquired conditions including trauma, stroke, tumor or spinal cord injuries.
Contact & Investigator
Elizabeth Engle, MD
PRINCIPAL INVESTIGATOR
Boston Children's Hospital
Frequently Asked Questions
Who can join the NCT03059420 clinical trial?
This trial is open to participants of all sexes, aged 1 Day or older, studying Congenital Fibrosis of Extraocular Muscles. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03059420 currently recruiting?
Yes, NCT03059420 is actively recruiting participants. Contact the research team at brenda.barry2@childrens.harvard.edu for enrollment information.
Where is the NCT03059420 trial being conducted?
This trial is being conducted at Boston, United States.
Who is sponsoring the NCT03059420 clinical trial?
NCT03059420 is sponsored by Boston Children's Hospital. The principal investigator is Elizabeth Engle, MD at Boston Children's Hospital. The trial plans to enroll 20,000 participants.